Research Programme in DNA Sequencing

RNS Number : 1276L

NetScientific PLC

02 July 2014

 



NetScientific plc

('NetScientific' or the 'Group')

Research Programme in DNA Sequencing

NetScientific (AIM:NSCI), the biomedical and healthcare technology investment group, is pleased to announce that, to complement and reinforce its personalised medicine platform, Nanopore-II (a new US division of NetScientific) has secured an important research programme in DNA sequencing with a research institute in the United States.

This programme is in a fast-growing, valuable and very competitive field. Notwithstanding the crowded IP landscape, feedback from the US Patent Office on the initial filings is encouraging.

For further information, please contact
NetScientific plc	Tel: [phone]
Farad Azima, Chief Executive Officer
Peter Thoms, Chief Financial Officer
Liberum (Nomad & Broker)	Tel: [phone]
Chris Bowman / Christopher Britton / Thomas Bective
Bell Pottinger	Tel: [phone]
Daniel de Belder

Company website: www.netscientific.net

ABOUT NETSCIENTIFIC

NetScientific is a healthcare and life sciences company with global reach that funds and develops technologies that offer transformative benefits to peoples' lives and society through improved diagnosis, prognosis and treatment. The group is primarily focused on identifying and developing cutting edge technologies with applications in several: (i) cardiovascular; (ii) liver; (iii) cancer; (iv) metabolic; and (v) digital health.

 

END

 

 

MSCSSSFLFFLSEEW